CN210750447U

CN210750447U - Medicine slow-release support for treating allergic rhinitis

Info

Publication number: CN210750447U
Application number: CN201921371993.8U
Authority: CN
Inventors: 马鹏飞; 李毅; 杨若朦; 童红霞; 盛喜霞; 张莉; 高翔; 王莉芳; 王红; 王雁; 王燕; 冯雪梅; 王袖和
Original assignee: Individual
Current assignee: Individual
Priority date: 2019-08-22
Filing date: 2019-08-22
Publication date: 2020-06-16
Anticipated expiration: 2029-08-22

Abstract

The utility model relates to the technical field of medical equipment for treating allergic rhinitis, in particular to a drug sustained-release stent for treating allergic rhinitis, which comprises a stent main body, wherein the stent main body is woven by metal wires by adopting rhombic grid patterns; the metal wire is a medical nickel-titanium memory alloy wire; the stent main body is coated with a drug sustained-release membrane. The utility model adopts medical nickel-titanium memory alloy wire as the raw material of the bracket, has excellent biocompatibility and corrosion resistance, is easy to be placed in the nasal cavity, and has no stimulation and side effect; the support acts on the inner wall of the nasal cavity, struts the edema part, gradually expands the narrow part, and reconstructs a breathing passage, and simultaneously has good hyperelasticity at the body temperature, and can follow the peristalsis of the nasal cavity, thereby not only keeping the nasal cavity unobstructed, but also having no uncomfortable feeling, and ensuring that the front part of the support does not fall into the breathing air passage.

Description

Medicine slow-release support for treating allergic rhinitis

Technical Field

The utility model relates to the technical field of medical equipment for treating allergic rhinitis, in particular to a drug sustained-release bracket for treating allergic rhinitis.

Background

Allergic Rhinitis (AR), also called allergic rhinitis, is a clinically common allergic reaction, the typical symptoms of which are nasal obstruction, nasal discharge, sneezing and/or rhinocnesmus, the onset of allergic rhinitis is related to the interaction of heredity and environment, and at present, the number of patients is large, the treatment is repeated, delayed and unhealed, and the curative effect is poor.

Although the allergic rhinitis cannot be completely cured, the symptoms of patients can be well controlled and the quality of life can be obviously improved through standard comprehensive prevention and treatment, and the prevention and treatment of the allergic rhinitis currently comprises three types, namely allergen avoidance, drug treatment and immunotherapy: avoiding allergen by using special mask, glasses, nasal filter, pollen blocking agent and inert cellulose powder; the drug therapy can be glucocorticoid or antihistamine or anti-leukotriene or mast cell membrane stabilizer or decongestant or anticholinergic or Chinese medicine; immunotherapy is directed to the treatment of IgE-mediated allergy type i disease in response to a stepwise increasing dose of allergen extract (therapeutic vaccine) administered to a patient to induce immune tolerance in the body, resulting in reduced or no clinical symptoms in the patient when exposed to the corresponding allergen.

In the medical treatment, the adopted dosage forms are usually nasal drops, sprays, aerosols and the like, the retention time of the medicine on an affected part in a nasal cavity is short, the medicine effect is difficult to play, the rhinitis and nasal obstruction symptoms are difficult to relieve, and the medicine resistance and the curative effect are reduced after long-term use. The severe edema of the nasal mucosa causes nasal obstruction that the inferior turbinate, the nasal fundus and the nasal septum are tightly closed, the spray can not be sprayed into the edema part, the symptoms can only be relieved by an oral preparation, and the side effect is easy to appear after long-term oral administration.

In view of the above technical problems, there is an urgent need to improve the existing drug treatment methods to achieve better treatment effects.

SUMMERY OF THE UTILITY MODEL

An object of the utility model is to provide a medicine slowly-releasing support of treatment allergic rhinitis makes the medicine pass through the support of support and can slowly-release in the nasal cavity affected part, improves the bioavailability of medicine to solve the problem that proposes in the above-mentioned background art.

In order to achieve the above object, the utility model provides a following technical scheme:

a drug sustained-release stent for treating allergic rhinitis comprises a stent main body, wherein the stent main body is woven by metal wires by adopting a rhombic grid pattern;

the metal wire is a medical nickel-titanium memory alloy wire;

the stent main body is coated with a drug sustained-release membrane.

As a further aspect of the present invention: the front part of the bracket main body is in a horn mouth shape.

As a further aspect of the present invention: the rear part of the bracket main body is cylindrical.

As a further aspect of the present invention: the diameter of the front part of the bracket is 8mm, and the diameter of the rear part of the bracket is 7 mm.

As a further aspect of the present invention: the diameter of the front part of the bracket is 9mm, and the diameter of the rear part of the bracket is 8 mm.

As a further aspect of the present invention: the diameter of the front part of the bracket is 10mm, and the diameter of the rear part of the bracket is 9 mm.

Compared with the prior art, the beneficial effects of the utility model are that:

1. the drug sustained-release stent for treating allergic rhinitis adopts medical nickel-titanium memory alloy wires as raw materials of the stent, has excellent biocompatibility and corrosion resistance, achieves the phase-change temperature memory recovery characteristic and elasticity, has no supporting force when the stent is in a softening state in an environment of 0-10 ℃, can change the shape within a certain range, and is easy to place in a nasal cavity; the stent can gradually recover to the original shape at the self temperature of a human body, generates continuous and soft radial expansion force, acts on the inner wall of the nasal cavity to open the edema part, gradually expands the narrow part and rebuilds a breathing channel; the support has good hyperelasticity at body temperature and can follow the peristalsis of the nasal cavity, so that the nasal cavity is kept unobstructed and does not feel uncomfortable too much;

2. the inner wall of the nasal cavity can be effectively expanded by utilizing the shapes of the front part and the rear part of the bracket, the positioning at the narrow part of the nasal cavity is easy, and the falling off of the bracket in the use process is prevented;

3. the medicine slow release film laid on the stent main body can be used for treating rhinitis locally for a long time and in a large area, and compared with the low bioavailability caused by the autonomous nasal cilia clearing movement of a common spray, the medicine controlled release stent for treating the allergic rhinitis has high bioavailability.

Drawings

In order to illustrate the technical solutions in the embodiments of the present invention more clearly, the drawings that are needed in the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention.

Fig. 1 is a structural schematic diagram of a drug sustained-release stent for treating allergic rhinitis.

In the figure: 1-main body of the bracket, 2-metal wire, 3-front part of the bracket and 4-back part of the bracket.

Detailed Description

In order to make the technical problem, technical solution and advantageous effects to be solved by the present invention more clearly understood, the following description is given in conjunction with the accompanying drawings and embodiments to illustrate the present invention in further detail. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.

Example 1

Referring to fig. 1, in an embodiment of the present invention, a drug sustained-release stent for treating allergic rhinitis includes a stent main body 1, wherein the stent main body 1 is woven by metal wires 2 in a diamond grid pattern; the metal wire 2 is a medical nickel-titanium memory alloy wire; the stent main body 1 is coated with a drug sustained-release membrane.

The drug sustained-release stent for treating allergic rhinitis adopts the metal wire 2 of the medical nickel-titanium memory alloy wire as the raw material of the stent, the medical nickel-titanium memory alloy wire has excellent biocompatibility and corrosion resistance, and simultaneously has the characteristics of phase change temperature recovery memory and superelasticity, the stent is in a softening state without supporting force in the environment of 0-10 ℃, can change the shape within a certain range, is easy to place in a nasal cavity, can gradually recover the original shape at the temperature of a human body to generate continuous and soft radial expansion force, acts on the edema part of the inner wall of the nasal cavity to gradually expand the narrow part to reconstruct a respiratory channel, and simultaneously the stent is unobstructed at the body temperature, can follow the peristalsis of the nasal cavity, not only keeps the nasal cavity but also has no great discomfort;

the medicine slow-release film laid on the stent main body 1 can be used for treating rhinitis locally in a large area for a long time, and compared with the low bioavailability of the nasal cavity cilia self-cleaning exercise of a common rhinitis spray, the medicine slow-release stent for treating the allergic rhinitis has high bioavailability.

Further, the bracket front part 3 of the bracket main body 1 is in a bell mouth shape.

Further, the holder rear part 4 of the holder main body 1 is cylindrical.

The inner wall of the nasal cavity can be effectively expanded by utilizing the shapes of the front part 3 and the rear part 4 of the bracket, the positioning at the narrow part of the nasal cavity is easy, and the falling off of the bracket in use is prevented.

Further, the diameter of the front part 3 of the bracket is 8mm, and the diameter of the rear part 4 of the bracket is 7 mm.

Further, the diameter of the front part 3 of the bracket is 9mm, and the diameter of the rear part 4 of the bracket is 8 mm.

Further, the diameter of the front part 3 of the bracket is 10mm, and the diameter of the rear part 4 of the bracket is 9 mm.

According to individual difference, the bracket is woven into three sizes with different sizes, so that the bracket can adapt to different crowds.

In the description of the present invention, unless otherwise expressly specified or limited, the terms "mounted," "connected," and "connected" are to be construed broadly, e.g., as meaning a fixed connection, a removable connection, or an integral connection; can be mechanically or electrically connected; they may be connected directly or indirectly through intervening media, or they may be interconnected between two elements. The specific meaning of the above terms in the present invention can be understood in specific cases to those skilled in the art.

The above description is only exemplary of the present invention and should not be taken as limiting the scope of the present invention, as any modifications, equivalents, improvements and the like made within the spirit and principles of the present invention are intended to be included within the scope of the present invention.

Claims

1. The drug sustained-release stent for treating allergic rhinitis is characterized by comprising a stent main body (1), wherein the stent main body (1) is woven by metal wires (2) in a rhombic grid pattern;

the metal wire (2) is a medical nickel-titanium memory alloy wire;

the stent main body (1) is coated with a drug sustained-release membrane.

2. The drug sustained-release stent for treating allergic rhinitis according to claim 1, wherein the stent front part (3) of the stent main body (1) is in a bell mouth shape.

3. The drug sustained-release stent for treating allergic rhinitis according to claim 2, wherein the stent rear portion (4) of the stent main body (1) is cylindrical.

4. The drug-eluting stent for treating allergic rhinitis according to claim 3, wherein the diameter of the stent front portion (3) is 8mm, and the diameter of the stent rear portion (4) is 7 mm.

5. The drug-eluting stent for treating allergic rhinitis according to claim 3, wherein the diameter of the stent front portion (3) is 9mm, and the diameter of the stent rear portion (4) is 8 mm.

6. The drug-eluting stent for treating allergic rhinitis according to claim 3, wherein the diameter of the stent front portion (3) is 10mm, and the diameter of the stent rear portion (4) is 9 mm.